附件A1对氧化LDL诱导的单细胞对内皮细胞的粘附的保护作用:对动脉样硬化的影响

相关实验视频

Updated: Jun 10, 2025

00:06

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly

Published on: August 20, 2019

15.0K

Xiaoling Zeng¹, Ruhui Qiu², Wen Peng²

¹Department of Cardiology, Jingzhou Central Hospital, No. 26, Chu Yuan Road, Jingzhou, Hubei, 434020, China. zxiaoling001@163.com.

Journal of thrombosis and thrombolysis

|October 13, 2024

概括

附录素A1通过减少内皮功能障碍和炎症来预防动脉样硬化. 这项研究表明,Annexin A1减轻了氧化低密度脂蛋白 (ox-LDL) 的作用,为动脉样硬化提供了潜在的治疗策略.

科学领域:

心血管生物学心血管生物学
分子医学是分子医学.
细胞生物学细胞生物学

背景情况:

由氧化低密度脂蛋白 (ox-LDL) 驱动的内皮功能障碍是动脉样硬化 (AS) 发展的核心因素.
附录素A1的作用,一个关键的附录素家族成员,在AS的发病过程中还不清楚.
调查AS的新疗法目标至关重要.

研究的目的:

调查Annexin A1对ox-LDL诱导的内皮功能障碍的保护作用.
阐明素A1在动脉样硬化中的作用的基础分子机制.
评估Annexin A1作为AS的潜在治疗剂.

主要方法:

人类静脉内皮细胞 (HUVEC) 用ox-LDL和Annexin A1.1进行治疗.
使用定量实时PCR和西式斑点测试来评估基因和蛋白质表达 (LOX-1,IL-6,MCP-1,E-selectin,VCAM-1,KLF2).
测量了线粒体反应性氧物种 (ROS) 和降低的谷氨 (GSH) 水平. 进行了单细胞粘附测试.

主要成果:

安素A1治疗通过降低线粒体ROS和恢复ox-LDL暴露的HUVEC中的GSH水平来降低LOX-1表达和改善氧化应激 (OS).
附件A1抑制了促炎性细胞因子 (IL-6,MCP-1) 和内皮粘附分子 (E-selectin,VCAM-1),减少了单细胞的附着.
附件A1通过PI3K/Akt通路调节了KLF2表达,而KLF2沉默取消了附件A1的保护作用.

结论:

附件A1对氧-LDL诱导的内皮功能障碍和炎症具有显著的保护作用.
附件A1至少部分通过通过PI3K/Akt信号通路调节KLF2表达而起作用.
附件A1代表了治疗动脉样硬化的有希望的治疗候选者.

关键词:

附录A1 附录 A1 是一个附录.动脉样硬化是一种动脉样硬化.内皮质功能障碍内皮质功能障碍这是一个VCAM-1系统.ox-LDL 的使用情况.

相关概念视频

01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...

Inflammation

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

01:31

Lipid-derived Compounds in the Human Body

4.3K

Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...